T he 25th anniversary of the British Thoracic Society (BTS) and the 60th anniversary of the Society's journal, Thorax, seems an appropriate time to take stock of where we have come from, where we are now and where we wish to be in the future. Our beginning had its roots in the industrial revolution with poor and overcrowded housing and the ever present scourge of tuberculosis (TB). It was in 1928 that an ENT surgeon, St Clair Thomson, brought together The Sanatorium Superintendents' Society, The Tuberculosis Society and The Nursing Committee into a single professional body, The Tuberculosis Association, which was reformed in 1945 as The British Tuberculosis Association (BTA), interested in the prevention and treatment of tuberculosis (fig 1) . 1 The Association was small but highly effective in driving forward new ways of managing TB centred on sanatoria, fresh air and good food, but was quite separate from main stream medicine and surgery. With the incorporation of the Joint Tuberculosis Council, a second powerful group with responsibility for maintaining standards in TB care, and the increasing recognition that the health impacts of lung disease extended far wider than TB, the British Thoracic and Tuberculosis Society emerged in 1968. It was decided to simplify its name in 1977 to the British Thoracic Association. The final iteration occurred in 1982 when, after some deliberation, the more academic Thoracic Society (that had its origins largely in academic physiologists and a forum for presenting research) merged with the BTA to accommodate the changing face of lung disease. 2 The new British Thoracic Society (BTS) met the principles laid out by Sir William Osler who stated that ''the attributes of a good professional society should be to help members discover their true professional potential and keep them receptive and abreast of advances in their subject''. 1 3 While maintaining high clinical standards and providing educational and postgraduate training opportunities, research should lie at the heart of any medical speciality. Research reflects the scintillating edge where new science is presented for translation into practice, while also providing opportunities for professionals to contribute to the growth and improvement of their speciality and, in doing so, enrich their own experience. This, of course, is not new. Records from the minutes of the BTA in 1958 revealed the steady fall in deaths from TB from 1928 onwards, in large part due to improved housing, social conditions and nutrition as well as earlier diagnosis and the impact of the sanatoria treatment regimes that included various forms of lung collapse surgery driven in large part by the BTA and the Joint Tuberculosis Council. 4 5 However, what was so dramatic was the halving of deaths in the 6 years from 1948 to 1956 when streptomycin was first introduced. The excitement of this new treatment was captured at the BTA Oxford meeting in 1946 when the guest speaker Dr W H Feldman of the Mayo Clinic described the use of streptomycin in experimental TB in guinea pigs. Despite this major breakthrough, he stated that streptomycin was difficult to prepare and he considered that it would be some time before sufficient drug was available for large-scale use in humans. 6 7 It was an epoch-making paper and, many years afterwards, the then President, Dr Norman Tattersall, who was in the chair at the Oxford meeting considered it to be ''the most exciting moment in his professional life''. 1 In September 1946 Dr Honor Smith described the successful use of streptomycin for the treatment of tuberculous meningitis in a patient and this was probably the first scientific description of its clinical use in Britain. [8] [9] [10] 
EARLY YEARS OF MEDICAL RESEARCH AND THE MRC
Following a Royal Commission enquiry in response to the rising TB epidemic at the start of the 19th century, the then prime minister Lloyd George asked a young surgeon Christopher Addison (previously professor of surgery at Sheffield and of Addison's plane fame) to help establish the first government-funded Medical Research Committee on 20 June 1913 under the chairmanship of Lord Moulton. The purpose of this ''MRC'' was to oversee better research into the causes and management of human disease, especially TB. 11 12 In 1920 The Medical Research Council (MRC) emerged by Royal Charter with the ''responsibility for the adequacy of the national effort in medical research''. 12 To this day the MRC represents the UK government's support for medical research across the full spectrum of biological, physical and social sciences.
The current mission of the MRC is Discovery Science for Health. This includes encouraging and supporting high quality research with the aim of maintaining and improving human health, producing skilled researchers, advancing and disseminating knowledge and technology to improve the quality of life and economic competitiveness in the UK and to promote dialogue with the public about medical research. Its annual budget in 2006/7 was £575 million across six Research Boards which have delegated responsibility for funding research grants, units, centres and training awards equally between the intramural and extramural programmes. Today the MRC's research effort is at least equalled by the medical research charities and-as will become apparent-a large increase in support from the Department of Health (DH). Despite achieving considerable success since its inception, advances in science and technology together with an unprecedented need for evidence to inform diagnosis and treatment, the MRC and the other research funding bodies are in the process of evolving to meet the ever-increasing demands placed upon them.
THE NHS RESEARCH AND DEVELOPMENT PROGRAMME
In 1988 the House of Lords Select Committee on Science and Technology completed an enquiry identifying an urgent need for the NHS itself to have a research function outside policy support and to bring new approaches to health care. 13 The NHS Research and Development (R&D) Programme, led by Sir Michael Peckham, was launched in 1990 and soon established a series of regional R&D centres that held their own budgets to implement a research culture across the full range of NHS activity, but with a special focus on clinical trials, health service research and improved service development. 14 However, despite a promise for scaled-up funding, this enterprise was restrained with most NHS R&D money being locked into NHS hospitals as the Service Increment for Teaching and Research (SIFTR). However, despite numerous attempts to liberate and then protect R&D funding from being used to support health service costs (including those of the Culyer Report of 1994 15 16 ), this proved to be an impossible task.
A CHANGE OF HEART AND DIRECTION
Since the millennium, a series of highly influential reports have been published that have had a profound effect in helping to reshape the medical research landscape: 
ADDRESSING RESEARCH AND DEVELOPMENT GAPS
In December 2006 the Cooksey Report 21 raised important concerns regarding the harnessing of UK medical research into patient and commercial benefit (''development gaps''). The report identified two major barriers to research translation: taking forward basic science discoveries into practical developments and trialling developments on patient pathways and implementing these as part of evidence-based health care 
IMPLICATIONS FOR LUNG RESEARCH
Historically the UK has pioneered lung research, starting with TB and then taking on the challenges of industrial lung disease 4A) . 24 A separate survey conducted by the BTS has also revealed that academic research in lung disease is decreasing rapidly with few trainees wishing to follow this career path, an observation that accords with the AMS report on the state of clinical academic medicine. 19 A detailed examination of the type of research which conventionally receives support from the MRC, DH and the medical research charities indicates a heavy bias towards aetiological and pathophysiological studies with relatively little evidence of translation to patient benefit ( fig 4B) . It is important to note, however, that this analysis does not include research funded by industry.
At a time when respiratory diseases such as asthma and associated allergy, COPD, cancer and interstitial lung disease are reaching an all-time high and diseases that were thought to be under control such as TB and bacterial pneumonias are reemerging with antimicrobial resistance, the time has come for action. The climate in the UK is now ready to accommodate a major push from the lung research community for a large increase in activity across the full spectrum of respiratory research. In October 2005 a meeting of research funders (DH, MRC, Wellcome Trust, Asthma UK, the British Lung Foundation (BLF)) and researchers at the Royal College of Physicians (RCP) identified the fragmented nature of lung research in the UK 25 and, as pointed out by Geoffrey Laurent in a previous editorial in Thorax, 26 an overcautious and competitive climate that was damaging rather than enhancing lung research. Collaboration and clinical trial activity was poorly developed and, in some areas such as lung cancer, was almost absent when compared with activity in related areas such as breast, bowel, skin and prostate cancer. As identified in the Cooksey Report, 21 there were also difficulties in drawing discoveries in cancer into clinical benefits. 27 How do we make inroads to redress the balance between disease burden and research? What is the best model to capitalise on new discoveries and move these across to benefit patients? What emerged from the RCP meeting was an urgent need for a much more joined-up and integrated approach to lung disease research that cut across institutional and professional barriers, was inclusive and multidisciplinary. A first step for the new UKRRC was to generate a list of priority areas for research recognising that, to be effective, a focus based on unmet clinical need was required. Themes that emerged from this consultation process were: early life eventsdevelopment and lung aging, airways diseases and sleep apnoea syndromes, respiratory infections, lung cancer, mechanisms of lung injury, repair and regeneration, phenotyping respiratory diseases and delivery of care for lung disease. 25 The UKRRC considers good communication to be critical and has formed a small subgroup to oversee this. One output has been a regular newsletter widely distributed for display through members' websites; four newsletters have so far been published and can be accessed easily via the UKRRC on the BTS website (www.brit-thoracic.org.uk).
In An urgent need for more well-designed clinical trials in lung disease Lack of high quality clinical trials, especially in chronic conditions, involving non-drug as well as pharmaceutical and biological interventions, is also a great concern. To address this, the UKRRC has asked each of the major lung research charities, along with other groups within the UKRRC who have already carried out or are in the process of carrying out prioritisation of topics where there is a perceived and easily identifiable clinical need for trials, to generate a long list of research questions in urgent need of addressing. Asthma UK had already completed an update of their extensive survey of research needs in Basic Asthma Research (BARS 2) and is soon to complete a similar exercise in Clinical Research (CARS). The BLF had also asked its Research Committee to draw up a list of priority themes, especially in the area of chronic lung disease. The lists of trials that the UKRRC will initially be prioritising will be in asthma, COPD, non-asthma paediatric lung disease, interstitial pulmonary fibrosis and lung cancer. Within each area a short list of 2-3 highest priority research questions will be identified using the Delphi method and these will be taken forward by research leaders as national clinical trials. This will require champions in each of the selected areas to form a clinical trial subgroup in order to work up a grant proposal for submission to a national funding body. The trials will aim to address tractable questions, be amenable to multicentre study and, where appropriate, be multidisciplinary. Success will be the funding of several of these to be rolled out within the CLRN. Clearly, the six topics chosen for this first exercise is only a start from which we will undoubtedly learn, and it is the intention of the UKRRC to repeat several cycles of prioritisation in order to cover the full spectrum of lung disease.
Future activities of the UKRRC will include discussions with Cancer Research UK over the possibility of capacity building fellowships in lung cancer and engagement with the pharmaceutical, biotechnology and diagnostics industries over joint initiatives to strengthen respiratory research. This latter activity is not only important in further developing joint research proposals and trials, but also to increase the capacity of lungbased science in the fields of pharmacology, physiology and toxicology fundamental to the development of a successful industrial and clinical research base. 17 18 A shortfall of researchers People are key to delivering research. 23 The fall-off in young basic and clinical scientists wishing to pursue an academic and research career in the UK is therefore a real concern. 19 23 Capacity building, including new clinical and non-clinical studentships, fellowships and career development awards, needs to take place in all areas of respiratory health and to positively include primary care physicians, pharmacists, allied health professionals and nurses. Academic champions are needed to encourage and nurture promising research talent as proposed by the AMS report. 19 There also needs to be greater opportunity to enable those wishing to change career direction to incorporate some research activity or, in some cases, to making research a full-time career. The various groups that represent the professions could greatly facilitate the UKRRC aims by coming together under ''A Big Tent'' concept to share expertise, support and resources and to establish new ways of working that can be generalised across the country. This will require generosity of spirit and a true sense of multidisciplinarity, collegiality and collaboration. One good way to start this process would be to provide a forum for all young researchers to meet on a regular basis to present and discuss their work and career paths with senior colleagues and to receive dedicated support to facilitate their training. Such a group needs to be valued and nurtured since they will be the academic leaders of the future.
CONCLUDING COMMENTS
Maybe the 25th anniversary is a time to see what can be achieved by pulling together towards common objectives. As stated at the start of this review, research in lung disease must reflect the glittering edge of our speciality and, in doing so, it will be addressing the most important unmet clinical needs of our patients. In addition, as stated by Norman Tattersall in 1946, research should represent ''the most exciting moments in our careers''. What better way to start the next 25 years of the BTS.
